Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: Oncological outcomes of the initial 46 patients

BJU International

Volumn 109, Issue 6, 2012, Pages 860-866

  Koga, Fumitaka ^a   Kihara, Kazunori ^a   Yoshida, Soichiro ^a   Yokoyama, Minato ^a   Saito, Kazutaka ^a   Masuda, Hitoshi ^a   Fujii, Yasuhisa ^a   Kawakami, Satoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

bladder preservation; low dose chemoradiotherapy; muscle invasive bladder cancer; partial cystectomy; survival

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; CYTOREDUCTIVE SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; ORGAN PRESERVATION; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PELVIS; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84857651660     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10425.x     Document Type: Article

References (29)

1. Gilbert SM, Wood DP, Dunn RL, et al,. Measuring health-related quality of life outcomes in bladder cancer patients using the Bladder Cancer Index (BCI). Cancer 2007; 109: 1756-62 (Pubitemid 46668537)
2. Herr HW,. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93 (Pubitemid 32063483)
3. Herr HW, Bajorin DF, Scher HI,. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16: 1298-301 (Pubitemid 28175743)
4. Shelley MD, Barber J, Wilt T, Mason MD,. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002; 1: CD002079.Review
5. Hagan MP, Winter KA, Kaufman DS, et al,. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 665-72 (Pubitemid 37194292)
6. Rivera I, Wajsman Z,. Bladder-sparing treatment of invasive bladder cancer. Cancer Control 2000; 7: 340-6 (Pubitemid 30602200)
7. Rodel C, Grabenbauer GG, Kuhn R, et al,. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-71 (Pubitemid 34791095)
8. Shipley WU, Kaufman DS, Zehr E, et al,. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-7 (Pubitemid 34722947)
9. Shipley WU, Prout GR Jr, Einstein AB, et al,. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258: 931-5 (Pubitemid 17125826)
10. Tester W, Caplan R, Heaney J, et al,. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996; 14: 119-26 (Pubitemid 26020004)
11. Tester W, Porter A, Asbell S, et al,. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-90 (Pubitemid 23123381)
12. Weiss C, Wittlinger M, Engehausen DG, et al,. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 2008; 70: 1502-6 (Pubitemid 351417749)
13. Dalbagni G, Genega E, Hashibe M, et al,. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-6 (Pubitemid 32210214)
14. Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75 (Pubitemid 32120143)
15. Zietman AL, Sacco D, Skowronski U, et al,. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 1772-6 (Pubitemid 37254925)
16. Coppin CM, Gospodarowicz MK, James K, et al,. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901-7 (Pubitemid 26371447)
17. Sauer R, Birkenhake S, Kuhn R, Wittekind C, Schrott KM, Martus P,. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998; 40: 121-7
18. Chahal R, Sundaram SK, Iddenden R, Forman DF, Weston PM, Harrison SC,. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003; 43: 246-57 (Pubitemid 36314236)
19. Crawford ED, Skinner DG,. Salvage cystectomy after irradiation failure. J Urol 1980; 123: 32-4 (Pubitemid 10135289)
20. Eisenberg MS, Dorin RP, Bartsch G, Cai J, Miranda G, Skinner EC,. Early complications of cystectomy after high dose pelvic radiation. J Urol 2010; 184: 2264-9
21. Smith JA Jr, Whitmore WF Jr,. Salvage cystectomy for bladder cancer after failure of definitive irradiation. J Urol 1981; 125: 643-5 (Pubitemid 11123147)
22. Koga F, Kihara K, Fujii Y, et al,. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study. BJU Int 2009; 104: 189-94
23. Koga F, Yoshida S, Kawakami S, et al,. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis. Urology 2008; 72: 384-8
24. Yoshida S, Koga F, Kawakami S, et al,. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-91
25. Kihara K, Kawakami S, Fujii Y, Masuda H, Koga F,. Gasless single-port access endoscopic surgery in urology: minimum incision endoscopic surgery, MIES. Int J Urol 2009; 16: 791-800
26. Sobin LH, Wittekind C, eds. Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002
27. Tsukamoto T, Kumamoto Y, Masumori N, et al,. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391-5
28. Karl A, Carroll PR, Gschwend JE, et al,. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 2009; 55: 826-35
29. Ramani VA, Maddineni SB, Grey BR, Clarke NW,. Differential complication rates after radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 2010; 57: 1058-63